Company Description
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.
The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases.
The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products.
In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection.
Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.
| Country | NJ |
| Founded | 1984 |
| IPO Date | Jul 23, 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Nasrat Hakim |
Contact Details
Address: 165 Ludlow Avenue Northvale, New Jersey 07647 United States | |
| Phone | 2017502646 |
| Website | elitepharma.com |
Stock Details
| Ticker Symbol | ELTP |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001053369 |
| CUSIP Number | 28659T200 |
| ISIN Number | US28659T2006 |
| Employer ID | 22-3542636 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nasrat Hakim | Chairman, Chief Executive Officer and President |
| Douglas Plassche | Executive Vice President of Operations |
| Kirko Kirkov | Chief Commercial Officer |
| Carter J. Ward CPA, CSCP | Chief Financial Officer |
| Dianne Will | Vice President of Investor Relations and Corporate Affairs |
| Dr. George Kenneth Smith J.D., M.B.A., Ph.D. | Vice President of Legal |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | UPLOAD | Filing |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 10-Q | Quarterly Report |
| Jan 22, 2024 | UPLOAD | Filing |
| Dec 26, 2023 | 8-K | Current Report |
| Dec 12, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |